Evicenter
MarkdownMedical informationP&T meetings
Obefazimod (ABX464)

Ulcerative colitis

Manufacturer
Abivax
Launch
Not announced
Last updated
173 sources

Executive summary

Obefazimod efficacy and safety

8 evidence topics · 54 sources

Summary: regulatory status and evidence base

Obefazimod (ABX464) is an investigational oral small molecule for moderately to severely active ulcerative colitis. It is not approved in any jurisdiction, and no new drug application (NDA) has been submitted to the FDA; after a pre-NDA interaction, Abivax states that it “remains on track to submit its first NDA for obefazimod by the end of 2026”.

The phase 3 evidence comprises two 8-week placebo-controlled induction trials, ABTECT-1 and ABTECT-2, and the 44-week ABTECT Maintenance trial. The ABTECT results come from congress abstracts, posters, and slide presentations, company press releases and filings, and the ClinicalTrials.gov results of the two induction trials, first posted on 2026-09-10. The ClinicalTrials.gov record of the maintenance trial shows “No Results Posted”. No peer-reviewed full publication of any ABTECT trial exists as of the latest source. The phase 2 evidence comprises a phase 2a induction trial (ABX464-101) and its open-label extension (ABX464-102), a phase 2b dose-ranging induction trial (ABX464-103) and its open-label maintenance study (ABX464-104), and the ongoing open-label long-term extension Study 108 (ABX464-108).

Summary: induction efficacy in ABTECT-1 and ABTECT-2

In ABTECT-1, 636 participants were analyzed (318 receiving obefazimod 50 mg, 160 receiving obefazimod 25 mg, and 158 receiving placebo once daily), and in ABTECT-2, 636 participants (318, 159, and 159). The FDA primary endpoint was clinical remission by the modified Mayo Score at Week 8.

  • ABTECT-1: clinical remission occurred in 21.7% (69/318) with 50 mg and 23.8% (38/160) with 25 mg against 2.5% (4/158) with placebo; the placebo-adjusted differences were 19.3% and 21.4% (both p<0.0001). Each key secondary endpoint had p<0.0001 at both doses, including endoscopic improvement (33.3% with 50 mg and 37.5% with 25 mg against 5.7%) and clinical response (61.0% and 65.6% against 28.5%).
  • ABTECT-2: clinical remission occurred in 19.8% (63/318) with 50 mg against 6.3% (10/159) with placebo, a difference of 13.4% (p=0.0001). The 25 mg dose did not meet the primary endpoint (11.3% [18/159]; difference 5.1%, p=0.1034), so the p-values of its key secondary endpoints are nominal. Endoscopic improvement occurred in 35.5% with 50 mg and 22.0% with 25 mg against 10.1% with placebo.
  • For the EMA, endoscopic improvement and symptomatic remission were co-primary endpoints, which were “met by both doses in both trials”.
  • In the pooled analysis of both trials, for which all p-values are nominal, clinical remission at Week 8 occurred in 20.8% (132/636) with 50 mg and 17.6% (56/319) with 25 mg against 4.4% (14/317) with placebo (differences 16.4% and 13.2%).
  • Pooled patient-reported outcomes (nominal p-values): at Week 8, 37% of participants receiving 50 mg reported no bowel urgency against 18.1% receiving placebo, and a meaningful within-patient change in IBDQ total score occurred in 60.9% (50 mg) and 56.9% (25 mg) against 39.8% (placebo).
  • In a post hoc pooled analysis by baseline disease extent, the placebo-adjusted difference in clinical remission with 50 mg was 19.5% in proctosigmoiditis and 23.6% in left-sided colitis (both nominal p<0.0001); in extensive colitis, nominally significant differences with 50 mg were reported for clinical response, symptomatic response and remission, endoscopic improvement, and HEMI. In a pooled analysis by baseline disease duration, the difference in clinical remission with 50 mg was 20.6% with disease duration under 2 years, 17.8% with 2 to 10 years, and 12.5% with 10 years or more.
Summary: maintenance efficacy in ABTECT Maintenance
  • Design: Part 1 re-randomized 580 participants with a clinical response to 8 weeks of obefazimod induction to placebo (192), obefazimod 25 mg (193), or obefazimod 50 mg (195) once daily for 44 weeks. Placebo induction responders were maintained on blinded placebo and are not among the 580.
  • Primary endpoint: clinical remission at Week 44 occurred in 50.8% (98/193) with 25 mg and 51.3% (100/195) with 50 mg against 10.4% (20/192) with placebo; the adjusted differences were 39.3 and 40.3 percentage points (both p<0.0001). The UEG Week 2026 presentation reports the same results as Week 52, counting the 8-week induction.
  • Secondary endpoints reported by the company, each with p<0.0001 at both doses: endoscopic improvement in 54.9% (25 mg) and 64.1% (50 mg) against 12.5% (placebo); endoscopic remission in 41.5% and 47.7% against 9.9%; HEMI in 50.3% and 57.4% against 10.4%; corticosteroid-free clinical remission in 45.1% and 47.7% against 9.9%; and sustained clinical remission, among participants in clinical remission at Week 8 of induction, in 67.1% (49/73) and 65.6% (40/61) against 15.7% (8/51). The congress presentation states that both doses “met all multiplicity-controlled key secondary endpoints”.
  • Completion of Week 44 without relapse or treatment switch was 78.8% (152/193) with 25 mg and 82.1% (160/195) with 50 mg against 34.3% (66/192) with placebo.
  • Part 2, which has no placebo group, reported exploratory endpoints at Week 44. Among induction non-responders who continued obefazimod, clinical remission occurred in 23.5% with 25 mg (N=81) and 37.2% with 50 mg (N=148). Among Part 1 relapsers re-treated with 50 mg, it occurred in 45.0% of those previously receiving placebo (N=109) and 45.5% of those previously receiving 25 mg (N=33).
Summary: efficacy by prior inadequate response to advanced therapy
  • Induction, pooled analysis (nominal p-values): 602 of 1,272 participants (47.3%) had a prior inadequate response to an advanced therapy (AT-IR). Clinical remission at Week 8 with 50 mg occurred in 13.3% against 3.4% with placebo in AT-IR participants (difference 10.1%, p=0.0009) and in 27.7% against 5.3% in participants without AT-IR (difference 22.4%, p<0.0001). With 25 mg in AT-IR participants, it occurred in 6.8% (difference 3.5%, p=0.1728). Among participants with prior JAK inhibitor failure, clinical response occurred in 54.5% (30/55) with 50 mg and 47.1% (16/34) with 25 mg against 20.0% (7/35) with placebo.
  • Maintenance at Week 52 (unadjusted differences and nominal p-values, which the presenters state “should be interpreted as descriptive rather than confirmatory”): among participants with prior AT-IR, clinical remission occurred in 26 of 76 (25 mg) and 38 of 90 (50 mg) against 5 of 72 (placebo), differences of 28% and 33%; among AT-IR-naive participants, in 72 of 117 and 62 of 105 against 15 of 120, differences of 48% and 45%. Among participants with prior JAK inhibitor inadequate response, clinical remission occurred in 4 of 14 and 5 of 15 against 0 of 16. Prior advanced therapy failure was more frequent in the 50 mg group (46.2%) than in the 25 mg (39.4%) and placebo (37.5%) groups.
  • Phase 2b open-label maintenance study (50 mg, nonresponder imputation): clinical remission at week 96 occurred in 63.8% (76/119) of participants naive to biologics or JAK inhibitors; 38.8% (38/98) of those with prior inadequate response to them were in clinical remission at both weeks 48 and 96.
  • Study 108 (25 mg): among participants who completed week 144, clinical remission at week 144 was 90% in the 57 without prior AT-IR and 79% in the 47 with prior AT-IR.
Summary: phase 2 trials and long-term efficacy
  • ABX464-103 (phase 2b, randomized, double-blind, placebo-controlled induction trial; 254 participants randomized, 252 in the full analysis set): for the primary endpoint, the least squares mean change from baseline in modified Mayo score at week 8 was -3.1 with 25 mg, -3.2 with 50 mg, and -2.9 with 100 mg against -1.9 with placebo (p=0.0010, p=0.0003, and p=0.0039 against placebo).
  • ABX464-104 (phase 2b open-label maintenance study): 217 participants received obefazimod 50 mg once daily irrespective of their induction treatment or outcome. With nonresponder imputation, clinical remission occurred in 54.8% (119/217) at week 48 and 52.5% (114/217) at week 96, and clinical response in 81.6% (177/217) and 72.8% (158/217); among the 124 participants with clinical response at week 8 of induction, clinical remission at week 96 occurred in 59.7% (74/124). Of the 217 participants, 164 (75.6%) completed week 96. The investigators state that the results “must be interpreted with caution due to the absence of a control group”.
  • ABX464-101 (phase 2a, 8 weeks): 32 participants were randomized (23 to obefazimod 50 mg and 9 to placebo), and the registered primary outcome was the number of participants with treatment-emergent adverse events. Clinical remission at week 8 occurred in 35.0% with obefazimod against 11.1% with placebo, a difference the sponsor reported as “p=ns”, and mucosal healing in 50% against 11% (p=0.034).
  • ABX464-102 (open-label extension of ABX464-101): 22 participants received obefazimod 50 mg with up to 48 months on treatment; 11 completed the study, and with non-responder imputation, 9 of 22 were in clinical remission at month 48.
  • Study 108 (ABX464-108; ongoing single-group, open-label extension; interim analysis presented in a congress poster and a company release): 130 participants who completed ABX464-102 or ABX464-104 with a Mayo endoscopic subscore of 0 or 1 and a rectal bleeding subscore of 0 received obefazimod 25 mg once daily after 2 to 4 years of 50 mg. At study baseline, 89% (116/130) were in clinical remission. With non-responder imputation, clinical remission occurred in 73% (95/130), 69% (90/130), and 68% (88/130) at weeks 48, 96, and 144, and 104 participants (80%) completed week 144.
Summary: safety in the induction trials and phase 2 studies
  • Pooled ABTECT induction trials (636 participants receiving 50 mg, 319 receiving 25 mg, and 317 receiving placebo): treatment-emergent adverse events (TEAEs) occurred in 60.2%, 48.9%, and 50.8%, serious TEAEs in 3.1%, 2.2%, and 3.2%, and TEAEs leading to study discontinuation in 4.7%, 1.9%, and 4.1%. The most frequent TEAE was headache (23.3%, 15.0%, and 5.7%), with a median duration of 2 to 3 days; nausea occurred in 7.2%, 5.0%, and 1.3%, increased lipase in 4.2%, 2.8%, and 2.2%, and abdominal pain in 3.8%, 0.6%, and 0.6%. Serious, severe, or opportunistic infections occurred in 0.6%, 0.3%, and 0.3%, and the only opportunistic infection was aspergillosis with placebo. One malignancy occurred, a stage I prostate cancer in a participant who had received obefazimod 50 mg for two weeks. In the posted registry results, serious acute pancreatitis occurred in 1 of 318 participants receiving 50 mg in ABTECT-1 and in 1 of 159 receiving 25 mg and 1 of 159 receiving placebo in ABTECT-2.
  • ABX464-103 (phase 2b induction): headache was reported in 42% (27/64) with 100 mg, 30% (19/63) with 50 mg, 21% (13/62) with 25 mg, and 8% (5/64) with placebo.
  • ABX464-104 (217 participants receiving 50 mg for up to 96 weeks): TEAEs occurred in 68.2% and treatment-emergent serious adverse events in 8.3%. One malignant meningioma and one death (car accident) were reported, both unrelated to treatment.
  • Study 108 (130 participants receiving 25 mg through week 144): TEAEs occurred in 73.8%, serious TEAEs in 6.2%, and non-melanoma skin cancer in 1 participant (0.8%); there were no deaths and no opportunistic infections, and the safety table does not include laboratory findings.
Summary: safety in ABTECT Maintenance, including malignancies
  • Part 1 over 44 weeks (192 participants receiving placebo, 193 receiving 25 mg, and 195 receiving 50 mg): TEAEs occurred in 50.0%, 58.0%, and 71.8%, serious TEAEs in 4.2%, 2.6%, and 5.6%, and TEAEs leading to study drug discontinuation in 6.8%, 2.6%, and 4.6%. There were no deaths. Serious or severe infections and opportunistic infections occurred in 1.0%, 1.0%, and 0.5%, including one lymph node tuberculosis with 25 mg. No acute pancreatitis or cardiac abnormalities suggestive of cardiac fibrosis were reported, and 2 pregnancies (1.1%) occurred with 50 mg.
  • Part 1 malignancies: no malignancy other than non-melanoma skin cancer (NMSC) occurred with placebo or 25 mg, and three occurred with 50 mg, each in 1 participant (0.5%). The company release describes them as the “prostate, breast, and colon cancer cases”, which were “considered unrelated to treatment by investigators”, and the UEG Week 2026 presentation reports “One case of colonic dysplasia” in the 50 mg arm. NMSC occurred in 1 participant with placebo, 1 with 25 mg, and 4 with 50 mg. The company states that “Two of the four 50 mg patients were deemed not/unlikely related to drug by investigators”, and that the mean age of the NMSC cases was 62 years against 42 years in the overall trial population.
  • Part 2 over 44 weeks (induction non-responders and Part 1 relapsers, 186 receiving 25 mg and 447 receiving 50 mg, without a placebo group): TEAEs occurred in 71.0% and 68.7%, serious TEAEs in 8.6% and 5.1%, and TEAEs leading to study drug discontinuation in 11.3% and 6.0%. One death occurred with 25 mg, from suspected pulmonary embolism, and was assessed by the investigator as unrelated to obefazimod. Acute pancreatitis occurred in 1 participant in each group (0.5% and 0.2%).
  • Part 2 malignancies: malignancies excluding NMSC occurred in none with 25 mg and 2 with 50 mg (0.4%), a myeloproliferative neoplasm and a prostate cancer, both in Part 1 placebo relapsers and both determined by the investigator as not related to study drug. NMSC occurred in 2 participants with 25 mg (1.1%) and 2 with 50 mg (0.4%); the investigator determined one NMSC case with 50 mg and one with 25 mg “probably related to study drug”. The company states that the NMSC events “all occurred in patients with established NMSC risk factors including advanced age, thiopurine use, prior skin cancer history and failure of multiple prior advanced therapies”.
  • Exposure-adjusted incidence (post hoc company analyses): in the phase 3 maintenance dataset (Part 1 and Part 2), the incidence of malignancies excluding NMSC per 100 patient-years was 0.00 with placebo, 0.00 with 25 mg, 0.91 with 50 mg, and 0.56 with both doses combined, and the incidence of NMSC was 0.68, 1.09, 1.37, and 1.26. The company sets these rates beside expected ulcerative colitis background ranges drawn from published studies (0.30 to 0.70 for malignancies excluding NMSC and 0.70 to 1.40 for NMSC) and states that the rates of the combined active arms are “within the UC background reference range based on published UC studies”. Across the integrated phase 2 and phase 3 ulcerative colitis trials (1,704 patient-years), the rates with both doses combined were 0.35 for malignancies excluding NMSC and 0.59 for NMSC, against 0.00 and 0.46 with placebo.
  • Data safety monitoring board reviews in December 2025 and March 2026 found no new safety signals.
Summary: pharmacology, pharmacokinetics, special populations, and drug interactions
  • Mechanism and pharmacodynamics: obefazimod is an oral small molecule that “selectively enhances the expression of a single micro-RNA (miRNA), miR-124”. It binds the cap binding complex, and its N-glucuronide metabolite (ABX464-N-Glu) is pharmacologically active and binds the same complex. In the ABTECT induction trials, obefazimod increased miR-124 expression in blood and in rectal and sigmoidal tissue at Week 8 and reduced serum IL-17A (p<0.0001 against placebo) and IL-6 (p=0.0150 with 25 mg and p=0.0039 with 50 mg), which the abstract authors describe as “nominally statistically significant reductions”.
  • Pharmacokinetics: after a single fasting dose, obefazimod reached its maximum concentration about 2 hours after administration and was rapidly metabolized to the N-glucuronide, whose maximum concentration was about 160-fold higher than that of the parent drug and whose half-life was 90 to 110 hours. The parent drug has a half-life of about 1 hour. Obefazimod is metabolized by glucuronidation, and steady state was reached after 4 weeks of repeated dosing. In a food-effect study, Cmax and AUC of obefazimod were “demonstrated to increase with food after a single dose of ABX464 (219% and 188%, respectively)”, and the increase for the metabolite was “much more limited”; the phase 3 protocol states that food increased obefazimod exposure “by at least 3- to 4-fold”. The interaction study protocol identifies CYP1A2 as the major isoform of the oxidative route of metabolism and reports that obefazimod inhibited CYP1A2 in human liver microsomes and induced its expression in human hepatocytes.
  • Special populations: a phase 1 study in mild and moderate hepatic impairment enrolled 30 participants, and its results are to be published from 11 March 2027; a phase 1 study in renal impairment is registered in the EU Clinical Trials Information System. The ABTECT induction trials excluded participants with creatinine clearance below 60 mL/min or AST or ALT above 2 times the upper limit of normal. Of the 1,272 participants in the ABTECT induction trials, 89 were 65 years or older, and TEAEs in this group occurred in 65.9% (50 mg), 38.9% (25 mg), and 55.6% (placebo). In ABTECT, women of childbearing potential were to use at least one highly effective method of contraception, and 2 pregnancies were reported with 50 mg in ABTECT Maintenance Part 1. A European paediatric investigation plan includes a study in patients aged 2 years to less than 18 years.
  • Drug interactions (phase 1 study ABX464-902 in healthy adults; mean values as posted): with fluvoxamine, a CYP1A2 inhibitor, mean obefazimod Cmax was 33.4 ng/mL against 23.2 ng/mL alone, and mean AUC 73.0 against 55.2 hng/mL (25 participants); the plain-language research summary states that obefazimod “may be metabolised in the same pathway as fluvoxamine”. With caffeine, a CYP1A2 substrate, mean caffeine AUC was 7420 hng/mL alone, 5460 hng/mL with the first obefazimod dose, and 1560 hng/mL after 14 days of obefazimod, and mean caffeine Cmax was 931, 930, and 564 ng/mL (22 participants); the plain-language summary states that caffeine and fluvoxamine levels “remained similar in both the presence and absence of ABX464”. Results of interaction studies with rosuvastatin and with a combined oral contraceptive (ethinyl estradiol and drospirenone) are to be published from 20 August 2027 and 28 February 2027.